Akros Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Akros Pharma sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Akros Pharma: 18 sponsored US clinical trials, none currently recruiting.
Akros Pharma sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anemia in Chronic Kidney Disease, with 1 trials.
Top-decile sponsor footprint
Akros Pharma ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
NCT04465877
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03832738
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03358290
Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
NCT02919475
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
NCT02805244
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
NCT02581124
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
NCT02120976
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
NCT02106585
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
NCT01978587
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
NCT01971164
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
NCT01699737
Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects
NCT01473069
Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects
NCT01475981
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
NCT00997152
Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
NCT00929539
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
NCT00748852
Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels
NCT00749788
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 9 |
Therapeutic Areas
How the Akros Pharma early-phase archive is shaped
18 indexed studies, none listed as recruiting (0% open); 13 completed (72%).
Phase mix: 0 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Anemia in Chronic Kidney Disease (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Akros Pharma: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Akros Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
- Beckman Coulter · 18 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Akros Pharma page
18 registered trials is a research-attention snapshot, not an endorsement of Akros Pharma or any single study.
- None of Akros Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Anemia in Chronic Kidney Disease is the condition Akros Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anemia in Chronic Kidney Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Akros Pharma pipeline card: 18 registered trials from official public datasets.Report a data error.